Bioprocessing Network: BioProNET

生物制品是由细胞过程制成的复杂分子，这些生物制品对英国和全球具有重大的经济和社会价值。生物制剂包括一系列治疗性分子（例如生物制药分子，如胰岛素和抗体，如赫赛汀）和非治疗性分子（例如诊断、工业酶、药物筛选、结晶/结构研究）。英国在开发治疗性蛋白质（生物制药）的商业规模生产（生物加工）过程中尤其具有创新性，这些蛋白质具有治疗其他难治性疾病的潜力。该地区还直接雇用了英国的大量劳动力，并对英国产生了直接的社会和经济影响。然而，如果要实现对英国的全部潜在回报，这些生物制剂的持续开发和商业化需要进一步的逐步改变的创新。生物加工是一个经济上的成功故事，到2020年，生物制药的销售额估计将超过3200亿美元。这些分子在医疗保健中的经济价值和日益增加的重要性显著增加了医疗保健成本，特别是在生物制药的情况下，存在更有效、可预测和负担得起地设计、开发和制造生物制药的压力。该提案旨在开发一个充满活力的学术主导的英国专业知识网络（BioProNET），该网络将汇集学者，工业家和其他感兴趣的团体，以整合从事治疗用途生物制剂生产（生物加工）的从业人员的专业知识以及非治疗用途。该网络将侧重于支持功能活性生物制剂的开发、工程、制造和监测的生物过程，以解决设计复杂性更高的分子的生产问题。多个科学学科，包括生命科学家，生物化学工程师，化学家，物理学家，数学家，计算科学家和社会科学家的视野和观点将应用于生物制品生产中生物过程的研究挑战，包括治疗用途的产品（例如生物制药）和非治疗用途的产品（例如生物传感器，药物开发和筛选，诊断）。在该网络中，我们将考虑该地区发展的社会，环境和经济影响，以及是否可以提高生物制剂生产的可持续性。该网络将保持英国生物加工部门（通过利用不同社区的知识广度，这些知识将被汇集在一起，以开发和扩展超越今天的系统，进入未来25年在世界舞台上竞争所需的系统）处于国际前沿，同时为下一代生物制剂的生产建立逐步变化和创新的解决方案。通过提高生物加工的成本效益，该行业将转向更负担得起的生物制剂/生物制药，以实现可持续和更健康的生活方式。

Biologics are complex molecules made by cellular processes and such biological products have major economic and social value for the UK and globally. Biologics encompass a range of molecules of therapeutic (e.g. biopharmaceutical molecules such as insulin and antibodies like Herceptin) and non-therapeutic (e.g. diagnostics, industrial enzymes, drug screening, crystallization / structural studies) use. The UK has been especially innovative in developing processes for commercial scale production (bioprocessing) of therapeutic proteins (biopharmaceuticals) in particular, that have the potential to treat otherwise intractable diseases. The area also directly employs a large work force in the UK and has direct social and economic impacts on the UK. However, the continued development and commercialization of such biologics requires further step-changing innovation if the full potential return to the UK is to be realised. Bioprocessing presents an economic success story and sales of biopharmaceuticals are estimated to be >$320B by 2020. The economic value and ever-increasing importance of these molecules in healthcare adds significantly to healthcare costs and, in the case of biopharmaceuticals in particular, there is pressure to design, develop and manufacture biopharmaceuticals more efficiently, predictably, and affordably. This proposal sets out to develop a vibrant academic-led UK network (BioProNET) of expertise that will bring together academics, industrialists and other interested groups to integrate the expertise of practitioners working on production (bioprocessing) of biologics of therapeutic use as well as those of non-therapeutic use. The Network will focus on biological processes that underpin the development, engineering, manufacturing and monitoring of functionally active biologics to address production of molecules of greater design complexity. The vision and perspectives of multiple scientific disciplines, including life scientists, biochemical engineers, chemists, physicists, mathematicians, computational scientists, and social scientists will be applied to the research challenges of biological process in the manufacture of biologics, both products of therapeutic use (e.g. biopharmaceuticals) and those of non-therapeutic use (e.g. biosensors, drug development and screening, diagnostics). Within the network we will consider the social, environmental and economic implications of development of the area and whether the sustainability of manufacturing of biologics can be improved. The Network shall maintain the UK bioprocessing sector (by harnessing the breadth of knowledge held in the different communities that will be brought together to develop and extend beyond today's systems into those that will be needed to compete on the world stage over the next 25 years) at the international forefront, whilst establishing step-changing and innovative solutions for the production of the next generation of biologics. By enhancing cost effectiveness of bioprocessing, the sector will move towards more affordable biologics/biopharmaceuticals for sustainable and healthier lifestyles.